Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.63, $0.29 better than the analyst estimate of $1.34. Revenue for the quarter came in at $54.7 million versus the consensus estimate of $70.41 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.